308 related articles for article (PubMed ID: 29450890)
1. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
5. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
8. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
Sperling MR; French J; Jacobson MP; Pazdera L; Gough M; Cheng H; Grinnell T; Blum D;
Neurology; 2016 Mar; 86(12):1095-102. PubMed ID: 26911639
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly.
Nielsen MK; Petrenaite V; Andersen NB
Seizure; 2017 Dec; 53():94-99. PubMed ID: 29172139
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
13. Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
Lattanzi S; Cagnetti C; Foschi N; Lorusso A; Provinciali L; Silvestrini M
Acta Neurol Scand; 2018 Jan; 137(1):29-32. PubMed ID: 28741673
[TBL] [Abstract][Full Text] [Related]
14. [Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].
Losch FP; Holtkamp M; McMurray R; Lendemans D; Kockelmann E
Nervenarzt; 2016 Oct; 87(10):1094-1099. PubMed ID: 27550387
[TBL] [Abstract][Full Text] [Related]
15. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid E; Kuchukhidze G; Kirschner M; Leitinger M; Höfler J; Rohracher A; Kalss G; Wendling AS; Steinhoff BJ; Trinka E
Acta Neurol Scand; 2017 Apr; 135(4):449-453. PubMed ID: 27444636
[TBL] [Abstract][Full Text] [Related]
16. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
17. Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
Mäkinen J; Rainesalo S; Peltola J
Brain Behav; 2017 Mar; 7(3):e00634. PubMed ID: 28293474
[TBL] [Abstract][Full Text] [Related]
18. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
20. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]